Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 63

1.

Determinants of response and resistance to CAR T cell therapy.

Lesch S, Benmebarek MR, Cadilha BL, Stoiber S, Subklewe M, Endres S, Kobold S.

Semin Cancer Biol. 2019 Nov 6. pii: S1044-579X(19)30219-6. doi: 10.1016/j.semcancer.2019.11.004. [Epub ahead of print] Review.

PMID:
31705998
2.

[Immuno-Oncology Meets Intensive Care Medicine: CAR-T cells].

Böll B, Borrega JG, Schellongowski P, Subklewe M, von Bergwelt-Baildon M.

Dtsch Med Wochenschr. 2019 Sep;144(19):1342-1347. doi: 10.1055/a-0853-4689. Epub 2019 Sep 26. German.

PMID:
31559615
3.

Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis.

Grunwald VV, Hentrich M, Schiel X, Dufour A, Schneider S, Neusser M, Subklewe M, Fiegl M, Hiddemann W, Spiekermann K, Rothenberg-Thurley M, Metzeler KH.

Blood Adv. 2019 Sep 24;3(18):2696-2699. doi: 10.1182/bloodadvances.2019000265. No abstract available.

4.

Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy.

Subklewe M, von Bergwelt-Baildon M, Humpe A.

Transfus Med Hemother. 2019 Feb;46(1):15-24. doi: 10.1159/000496870. Epub 2019 Feb 5. Review.

5.

Advances in cancer immunotherapy 2019 - latest trends.

Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M.

J Exp Clin Cancer Res. 2019 Jun 19;38(1):268. doi: 10.1186/s13046-019-1266-0. Review.

6.

Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia.

Van Acker HH, Versteven M, Lichtenegger FS, Roex G, Campillo-Davo D, Lion E, Subklewe M, Van Tendeloo VF, Berneman ZN, Anguille S.

J Clin Med. 2019 Apr 27;8(5). pii: E579. doi: 10.3390/jcm8050579. Review.

7.

Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction.

Köhnke T, Bücklein V, Rechkemmer S, Schneider S, Rothenberg-Thurley M, Metzeler KH, Sauerland MC, Hiddemann W, Spiekermann K, Subklewe M.

Haematologica. 2019 Nov;104(11):e510-e513. doi: 10.3324/haematol.2018.215236. Epub 2019 Apr 4. No abstract available.

8.

Abundant glutamic acid decarboxylase (GAD)-reactive B cells in gad-antibody-associated neurological disorders.

Thaler FS, Thaller AL, Biljecki M, Schuh E, Winklmeier S, Mahler CF, Gerhards R, Völk S, Schnorfeil F, Subklewe M, Hohlfeld R, Kümpfel T, Meinl E.

Ann Neurol. 2019 Mar;85(3):448-454. doi: 10.1002/ana.25414. Epub 2019 Jan 28.

PMID:
30635933
9.

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.

Braess J, Amler S, Kreuzer KA, Spiekermann K, Lindemann HW, Lengfelder E, Graeven U, Staib P, Ludwig WD, Biersack H, Ko YD, Uppenkamp MJ, De Wit M, Korsten S, Peceny R, Gaska T, Schiel X, Behringer DM, Kiehl MG, Zinngrebe B, Meckenstock G, Roemer E, Medgenberg D, Spaeth-Schwalbe E, Massenkeil G, Hindahl H, Schwerdtfeger R, Trenn G, Sauerland C, Koch R, Lablans M, Faldum A, Görlich D, Bohlander SK, Schneider S, Dufour A, Buske C, Fiegl M, Subklewe M, Braess B, Unterhalt M, Baumgartner A, Wörmann B, Beelen D, Hiddemann W; AML-CG.

Leukemia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1.

10.

Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.

Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.

Blood. 2018 Dec 6;132(23):2484-2494. doi: 10.1182/blood-2018-05-849802. Epub 2018 Oct 1.

PMID:
30275109
11.

Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells.

Braciak TA, Roskopf CC, Wildenhain S, Fenn NC, Schiller CB, Schubert IA, Jacob U, Honegger A, Krupka C, Subklewe M, Spiekermann K, Hopfner KP, Fey GH, Aigner M, Krause S, Mackensen A, Oduncu FS.

Oncoimmunology. 2018 Jul 30;7(9):e1472195. doi: 10.1080/2162402X.2018.1472195. eCollection 2018.

12.

[Challenges in Immuno-Oncology - Possibilities for Optimization].

Shimabukuro-Vornhagen A, Subklewe M, von Bergwelt-Baildon M.

Dtsch Med Wochenschr. 2018 Jul;143(14):1022-1029. doi: 10.1055/a-0549-6987. Epub 2018 Jul 13. German.

PMID:
30005436
13.

Cytokine release syndrome.

Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS.

J Immunother Cancer. 2018 Jun 15;6(1):56. doi: 10.1186/s40425-018-0343-9. Review.

14.

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.

Prassek VV, Rothenberg-Thurley M, Sauerland MC, Herold T, Janke H, Ksienzyk B, Konstandin NP, Goerlich D, Krug U, Faldum A, Berdel WE, Wörmann B, Braess J, Schneider S, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Metzeler KH.

Haematologica. 2018 Nov;103(11):1853-1861. doi: 10.3324/haematol.2018.191536. Epub 2018 Jun 14.

15.

Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.

Zimmermann H, Babel N, Dierickx D, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Bachy E, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S, Trappe RU.

Transplantation. 2018 Nov;102(11):1914-1923. doi: 10.1097/TP.0000000000002269.

PMID:
29757894
16.

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.

Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, Schlüter M, Neitz J, Subklewe M.

Front Immunol. 2018 Feb 27;9:385. doi: 10.3389/fimmu.2018.00385. eCollection 2018.

17.

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH.

Leukemia. 2018 Jul;32(7):1598-1608. doi: 10.1038/s41375-018-0034-z. Epub 2018 Feb 23.

18.

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.

Herold T, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Ksienzyk B, Hartmann L, Greif PA, Phillippou-Massier J, Krebs S, Blum H, Amler S, Schneider S, Konstandin N, Sauerland MC, Görlich D, Berdel WE, Wörmann BJ, Tischer J, Subklewe M, Bohlander SK, Braess J, Hiddemann W, Metzeler KH, Mansmann U, Spiekermann K.

Haematologica. 2018 Mar;103(3):456-465. doi: 10.3324/haematol.2017.178442. Epub 2017 Dec 14.

19.

End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry.

Zimmermann H, Denecke T, Dreyling MH, Franzius C, Reinke P, Subklewe M, Amthauer H, Kneba M, Riess H, Trappe RU.

Transplantation. 2018 May;102(5):868-875. doi: 10.1097/TP.0000000000002006.

PMID:
29189632
20.

The DNA Inflammasome in Human Myeloid Cells Is Initiated by a STING-Cell Death Program Upstream of NLRP3.

Gaidt MM, Ebert TS, Chauhan D, Ramshorn K, Pinci F, Zuber S, O'Duill F, Schmid-Burgk JL, Hoss F, Buhmann R, Wittmann G, Latz E, Subklewe M, Hornung V.

Cell. 2017 Nov 16;171(5):1110-1124.e18. doi: 10.1016/j.cell.2017.09.039. Epub 2017 Oct 12.

Supplemental Content

Loading ...
Support Center